v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Research and development $ 12,702 $ 3,661 $ 23,964 $ 7,963
Milestone liability change in fair value 175   (754)  
General and administrative 6,576 3,630 13,457 8,864
Total operating expenses 19,453 7,291 36,667 16,827
Loss from operations (19,453) (7,291) (36,667) (16,827)
Other income, net 446 325 1,032 718
Sermonix pre-funded warrant change in fair value 0   (16,320)  
Net loss (19,007) (6,966) (51,955) (16,109)
Unrealized (loss) gain on available-for-sale securities 4 1 (5) (4)
Comprehensive loss attributable to common stockholders $ (19,003) $ (6,965) $ (51,960) $ (16,113)
Net loss per share attributable to common stockholders, basic $ (0.80) $ (1.78) $ (2.43) $ (4.12)
Net loss per share attributable to common stockholders, diluted $ (0.80) $ (1.78) $ (2.43) $ (4.12)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic 23,726,211 3,909,297 21,389,630 3,930,991
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted 23,726,211 3,909,297 21,389,630 3,930,991